ALN-CC5: Phase I/II data

Data from 12 healthy volunteers in the double-blind, dose-escalation part A of a 3-part, U.K. Phase I/II trial showed that single doses of 50-400 mg subcutaneous ALN-CC5 were safe with no serious adve...